2025-08-11 - Analysis Report
Okay, here's a report analyzing Transmedics Group Inc (TMDX) based on the data you provided.

## Transmedics Group Inc (TMDX) Analysis Report

**Company Overview:** Transmedics Group Inc. is a medical technology company focused on preserving organs for transplantation.

**1. Performance Relative to S&P 500 (VOO)**

*   **Cumulative Return (TMDX):** 217.51%
*   **Cumulative Return (VOO):** 72.92%
*   **Absolute Spread:** 149.7
*   **Relative Spread (Historical Context):** 60.0 (Indicates current spread is in the 60th percentile of its historical range)

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the period for which cumulative returns are available.  The relative spread of 60.0 suggests the outperformance is substantial compared to its historical variations.

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
| :----------- | :------ | :------ | :------ | :----- | :----- |
| 2019-2021  | -4.0%   | 63.4% | -52.0%  | 0.1   | 0.7  |
| 2020-2022  | 140.0%  | 68.3% | 133.0%  | 0.2   | 2.1  |
| 2021-2023  | 95.0%   | 69.4% | 75.0%   | 0.4   | 2.7  |
| 2022-2024  | 147.0%  | 82.8% | 120.0%  | 0.4   | 2.1  |
| 2023-2025  | 99.0%   | 82.8% | 50.0%   | 0.6   | 3.9  |

**Analysis:**

*   **CAGR:** Shows very high growth periods mixed with a period of negative return(2019-2021).
*   **MDD:** Maximum Drawdown (MDD) values are high, indicating significant volatility and potential risk.
*   **Alpha:** Consistently positive alpha values indicates that TMDX has generated returns exceeding what would be expected based on its beta.
*   **Beta:** Beta values range from 0.1 to 0.6 (except for 2020-2025 period), indicating that TMDX's price is generally less sensitive to market movements than the S&P 500.
*   **Cap:** The company's market capitalization has grown from 0.7 Billion to 3.9 Billion

**2. Recent Price Action**

*   **Current Price:** 114.5
*   **Previous Close:** 116.05
*   **Change:** -1.34 (-1.16%)
*   **5-day Moving Average:** 120.72
*   **20-day Moving Average:** 113.16
*   **60-day Moving Average:** 123.90

**Analysis:**  The recent price decrease, confirmed by negative change and crossing below 5-day and 60-day moving average, suggests bearish(Bear market) movement of prices.The current price is above the 20-day moving average, which can be interpreted as a sign of potential short-term support.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.33 (Low Risk)
*   **RSI:** 60.51 (Approaching overbought territory, but not yet extreme)
*   **PPO:** 1.07 (Positive, suggesting upward momentum)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **Recent (20-day) Relative Spread Change:** -3.3 (Indicates short-term decline in relative performance)
*   **Expected Return:** 62.9% (Long-term, relative to S&P 500)

**Analysis:**  The MRI indicates low market risk.  The RSI suggests the stock is nearing overbought territory, indicating a potential pullback. The PPO is positive, implying continued upward momentum, but the negative change in relative spread indicates a possible short-term weakening compared to the S&P 500. Hybrid Signal advises to buy 80% of cash but with caution. The expected return suggests a strong long-term outlook (relative to the S&P 500).

**4. Recent News & Significant Events**

*   **[2025-08-11]** Major business developments, regulatory changes, or market events.
*   **[2025-08-07]** Analysts discussing recent performance and outlook.
*   **[2025-08-08]** Notable stock volatility due to recent news, earnings, or executive actions.
*   **[2025-08-09]** Market experts highlight both risks and opportunities.

**Analysis:**  The news suggests significant activity around TMDX, including volatility and analyst attention. Investors should investigate these specific events to understand potential impacts.

**5. Recent Earnings Analysis**

| Date       | EPS  | Expected EPS |
| :----------- | :--- | :----------- |
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.70 | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** TMDX has consistently beaten EPS expectations in recent quarters, which is a positive sign of company performance.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :--------- | :-------- | :-------------- |
| 2025-06-30 | $0.16B  | 61.38%          |
| 2025-03-31 | $0.14B  | 61.47%          |
| 2024-12-31 | $0.12B  | 59.21%          |
| 2024-09-30 | $0.11B  | 55.94%          |
| 2024-06-30 | $0.11B  | 60.59%          |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
| :--------- | :-------- | :------- |
| 2025-06-30 | $0.32B  | 10.97%   |
| 2025-03-31 | $0.27B  | 9.64%    |
| 2024-12-31 | $0.23B  | 3.00%    |
| 2024-09-30 | $0.21B  | 2.01%    |
| 2024-06-30 | $0.19B  | 6.42%    |

**Analysis:**

*   **Revenue:**  Revenue is steadily increasing, demonstrating growth.
*   **Profit Margin:** Very high and stable profit margins indicate efficient operations.
*   **Equity:**  Equity is increasing, demonstrating financial strength.
*   **ROE:**  Return on Equity (ROE) is also generally increasing, showcasing improved profitability on shareholder investments.

**7. Overall Summary**

Transmedics Group Inc. (TMDX) presents a compelling picture of a high-growth company with strong fundamentals.

*   **Strengths:** Significant outperformance relative to the S&P 500, consistently beating EPS expectations, high and increasing revenue and profit margins, increasing equity and ROE, and low market risk.
*   **Weaknesses:** High volatility (as indicated by MDD), recent negative price action.
*   **Opportunities:** Long-term expected return is very high, suggesting strong future growth potential.
*   **Threats:** Recent news indicates potential volatility.

**Recommendation:** While the recent price dip and volatility warrant caution, the strong fundamentals and high expected return suggest that TMDX could be a good long-term investment. However, investors should closely monitor news and company announcements and consider the stock's volatility.
